| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tifcemalimab | JS-004; TAB-004 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| MB-272 | MB272; GS-0272 | Phase 1 Clinical | MiroBio Ltd, University Of Oxford | Arthritis, Rheumatoid; Autoimmune Diseases | Details |
| ANB-032 | ANB-032 | Phase 1 Clinical | Anaptysbio Inc | Dermatitis, Atopic; Eczema; Inflammation | Details |
| Venanprubart | LY-3361237 | Phase 1 Clinical | Eli Lilly And Company, Sanford-Burnham Medical Research Institute | Lupus Erythematosus, Systemic; Psoriasis; Sjogren's Syndrome | Details |
| HFB200604 AID | HFB-200604-AID; HFB200604; HFB-200604; HFB200604 AID | Phase 1 Clinical | HiFiBiO Therapeutics | Autoimmune Diseases; Inflammation | Details |
| HFB-200603 | HFB-200603 | Phase 1 Clinical | HiFiBiO Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Stomach Neoplasms | Details |